ARS Pharmaceuticals (SPRY) risk factors
Item 1A of every ARS Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks6 new1 dropped17 reworded
The company faces heightened commercialization risks as neffy is its only approved product, relying heavily on global supply chains and collaboration partners. Regulatory scrutiny has intensified, notably with FDA untitled letters regarding TV advertisements and potential pricing pressures. Financial exposure includes a $100.0 million credit agreement and macroeconomic uncertainties impacting debt or equity financing.
Filed Mar 09, 2026 - FY2024 10-K risk factors66 risks
ARS Pharmaceuticals relies heavily on the commercial success of its single approved product, neffy, an intranasal epinephrine spray. The company faces significant risks from third-party dependency for manufacturing and distribution, uncertain pricing and reimbursement, and intellectual property protection.
Filed Mar 20, 2025